News und Analysen

Humana Inc. (NYSE: HUM) is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers

AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader

Merck & Co. Inc. (NYSE: MRK) delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year

As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the

Hims & Hers Health, Inc. (NYSE: HIMS) is a prominent player in the telehealth sector, which is part of the larger healthcare sector.  The company has garnered significant attention from

Novartis (NYSE:NVS) is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024. The company is performing

Abbott  Laboratories (NYSE: ABT) is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a

UnitedHealth Group (NYSE: UNH) has headwinds, but its healthcare business and operational quality offset them, setting the stock to hit new all-time highs. The primary culprit is the recent

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of

The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech

Shares of IDEAYA Biosciences Inc. (NASDAQ: IDYA) are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company’s pipeline candidate, IDE397, is an

The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings

In a holiday-shortened week, shares of AbbVie Inc. (NYSE: ABBV) are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson

The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S (NYSE: NVO) a

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is

Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving

Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Risk tolerance varies from person to person. Some people have no fear of parachuting out of an airline, while others won’t even ride a rollercoaster at a theme park. Everyone is a combination of

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow